Abstract

Sociedad Quimica Y Minera De Chile SA is scheduled to report quarterly results on August 19, 2026 after-market, with this preview highlighting expected revenue of 2.29 billion US dollars, EPS of 2.02, and the key drivers across lithium, iodine, and specialty plant nutrition that could shape the print and guidance.

Market Forecast

Based on the latest consolidated projections, revenue for the current quarter is estimated at 2.29 billion US dollars, up 113.62% year over year, with EBIT forecast at 978.75 million US dollars, up 309.06% year over year, and EPS projected at 2.02, implying year-over-year growth of 323.92%. Forecasts for gross profit margin and net profit margin are not available; the focus at the headline level is the sharp expected rebound in earnings leverage versus the prior-year comparator.

The company’s main business mix remains concentrated in lithium and derivatives, iodine and derivatives, and specialty plant nutrition; momentum is expected to be led by lithium volumes and realized prices, while iodine demand and margins help stabilize the earnings base. The most promising segment is lithium and derivatives, which delivered 1.19 billion US dollars in revenue last quarter and is guided for full-year sales volume growth raised to 15%, positioning it to contribute a disproportionate share of both the top-line and margin expansion in the near term.

Last Quarter Review

In the previous quarter, Sociedad Quimica Y Minera De Chile SA reported revenue of 1.76 billion US dollars, a gross profit margin of 44.24%, GAAP net profit attributable to the parent company of 365.00 million US dollars with a net profit margin of 20.72%, and EPS of 1.28; at the group level, revenue rose 69.80% year over year and EPS increased from 0.48 a year earlier. Net profit grew 98.47% quarter over quarter, reflecting improving operating leverage as the company executed on its volume plans and optimized its cost base.

A key financial highlight was the margin recovery, with gross margin at 44.24% underscoring better per-unit economics and operating efficiency. By line of business, lithium and derivatives contributed 1.19 billion US dollars, iodine and derivatives contributed 275.90 million US dollars, and specialty plant nutrition contributed 239.00 million US dollars; overall revenue grew 69.80% year over year, and management indicated stronger lithium volumes alongside a higher full-year sales growth target of 15%.

Current Quarter Outlook

Main business trajectory

For the core portfolio, the quarter is expected to be defined by higher shipments, more balanced realized prices across long-term and indexed contracts, and disciplined unit costs. The revenue forecast of 2.29 billion US dollars, up 113.62% year over year, implies a meaningful sequential acceleration from the 1.76 billion US dollars posted last quarter, consistent with the seasonal and operational ramp indicated by management. EBIT is projected at 978.75 million US dollars and EPS at 2.02, signaling robust operating leverage as fixed costs are absorbed over larger volumes and as the mix normalizes toward higher-margin tons. While the company has not issued an explicit gross margin or net margin forecast for this quarter, the prior-quarter gross margin of 44.24% offers a constructive starting point, and the scale-up in higher-contribution products suggests room for resilience if realized prices track internal expectations.

The iodine and derivatives business should serve as an earnings stabilizer this quarter, contributing a consistent revenue and margin profile relative to the broader portfolio. Demand signals remain constructive within the company’s customer base and order book dynamics, and the previous quarter’s 275.90 million US dollars revenue contribution establishes a firm baseline. Specialty plant nutrition, with 239.00 million US dollars last quarter, remains positioned to benefit from operating efficiency and distribution discipline, aiding margin stability even as the company prioritizes volume growth in its flagship segment.

Putting the pieces together, management’s raised sales-volume ambition for the year provides a supportive context for near-term performance. The interplay between volume gains and realized pricing is key: delivery of the forecasted EPS of 2.02 depends on maintaining discipline in production scheduling, freight/logistics costs, and product mix allocation. The balance of these factors should translate into healthy quarter-on-quarter momentum from the 1.28 EPS delivered in the last report, subject to the timing of shipments and any short-term contract mix variance.

Most promising segment: lithium and derivatives

Lithium and derivatives remains the company’s largest and most influential segment, contributing 1.19 billion US dollars in revenue last quarter and expected to drive the majority of the projected year-over-year expansion in both revenue and earnings this quarter. Management has already raised its full-year lithium sales volume growth target to 15%, which anchors the tonnage trajectory and supports the top-line forecast. The expected improvement in EPS to 2.02, up 323.92% year over year, indicates the segment’s ability to translate production and sales volume growth into earnings, provided the realized price environment remains within the company’s guided bands.

Operationally, the company continues to prioritize maximizing output while protecting its low-cost position, which helps in defending margins even when realized prices fluctuate. The announced collaboration framework at its Chilean operations, including development planning with DLE-related initiatives over the medium term, signals a multi-year path to volume growth and resource recovery improvements. For this quarter, though, the principal swing factor is the shipment mix across carbonate and hydroxide, the proportion of contract versus indexed volumes, and the company’s ongoing work to keep conversion and logistics costs in check.

Given the 113.62% year-over-year revenue growth forecast at the group level, lithium’s contribution is likely to be outsized, and the flow-through to EBIT at 978.75 million US dollars implies a high incremental margin. The company’s capacity planning and customer delivery schedule point to a strong quarter from a volume standpoint, while realized pricing will determine the amplitude of the upside. Consistency in execution on production and quality metrics should help reduce operational risk, supporting the forecasted EPS of 2.02.

Key near-term stock-price drivers

The first driver is delivery versus the revenue and EPS forecasts: a print near 2.29 billion US dollars and 2.02 EPS would validate the year-over-year acceleration signaled since the last report, while any variance—positive or negative—will likely be amplified by how investors interpret the sustainability of volumes and pricing across the remainder of the year. The second driver is margin commentary: investors will look for qualitative and quantitative color on gross profitability relative to the 44.24% achieved last quarter and the net margin of 20.72%, especially with EBIT projected at 978.75 million US dollars this quarter. The third driver is the forward run-rate on volumes and any updates on the annual sales outlook, including how contract terms and product mix may trend into the second half.

A related factor to watch is capital allocation and growth execution—particularly updates on project timelines and investment cadence that support the mid-cycle volume trajectory. Clear commentary on how the company intends to pace spend and balance sheet flexibility alongside near-term shipments and margins would be supportive for the equity narrative. Finally, signals on the cadence of shipments through quarter-end and any implications for working capital will be important to assess cash conversion, which can influence sentiment even when headline earnings meet expectations.

Analyst Opinions

Across recent sell-side and market commentary observed since January 1, 2026, the majority tilt against overtly negative views favors a constructive stance on Sociedad Quimica Y Minera De Chile SA, with a prevailing bias toward bullish or overweight frameworks relative to outright bearish calls. Berenberg has maintained a Hold view, with a recent price target reset to 66 US dollars and prior communications reiterating a neutral stance; JPMorgan’s stance has been Neutral with a higher target of 100 US dollars, reflecting a balanced assessment around execution and mid-term growth; Scotiabank’s more recent revision carried a 93 US dollars price target, positioned near the mid-to-upper bound of recent trading ranges and consistent with a neutral-to-moderate view. In contrast, aggregated analyst tracking indicated an average rating of overweight with a mean price target near the mid-80s, which serves as the key bullish anchor within the current mosaic.

The constructive camp emphasizes three points. First, the projected step-up in quarterly revenue to 2.29 billion US dollars and EPS to 2.02 underscores a stronger earnings cadence than what was embedded in prior quarters, highlighting the positive operating leverage now manifesting in the P&L. Second, guidance momentum matters: the company’s upgrade of full-year lithium sales volume growth to 15% provides a credible backbone for volume-led earnings resiliency, helping align expectations with production and shipment plans already in motion. Third, visibility into the medium-term growth platform—framed by development initiatives and operational enhancements—supports a sustained ramp in output and cost-advantaged delivery, which, in analysts’ view, can translate into more durable free-cash-flow generation as the margin structure normalizes over higher absolute volumes.

These points are balanced by what neutral analysts see as watch items—principally, the relationship between realized prices and contract mix, and the translation of shipment volumes into margins that remain close to the 44.24% gross margin recorded last quarter. However, on a bullish-versus-bearish tally, bullish views dominate because negative or underweight calls are not prominent in the recent set of opinions, while the overweight consensus signal and supportive earnings forecast trajectory add conviction on near-term performance. The net effect is a constructive skew into the August 19, 2026 print, conditioned on the company delivering the forecasted revenue of 2.29 billion US dollars, EBIT of 978.75 million US dollars, and EPS of 2.02, and reinforcing a narrative of execution consistency in volumes, pricing discipline within contracted frameworks, and continued cost optimization.